drugset
drugset / Trial / NCT00274404

Controlled Trial of Valacyclovir in Infectious Mononucleosis

NCT00274404 ↗

Phase 1/2 Completed 20 enrolled University of Minnesota Hoffmann-La Roche · collabMinnesota Medical Foundation · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis (mono) while being a safe drug. Because EBV is the cause of mono, it is expected that reduction of the amount of virus could result in faster recovery from the disease.

Timeline

Start
2004-02
Primary completion
2005-09
Completion
2005-09

Publications

  • Results Balfour HH, Jr., Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Brundage RC. A controlled trial of valacyclovir in infectious mononucleosis. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 18, 2005. Abstract V1392

Drugs

EvaluationDrugModalityDoseRoute
Subject Valacyclovir Unknown 1 g —

Indications

infectious mononucleosis